Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.54 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514368 | 0.86 | KDM4E (0.50) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL11022101 | 0.82 | KDM4E (0.50) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL9478348 | 0.82 | ALDH1A1 (0.49) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL10746820 | 0.82 | KDM4E (0.53) | KDM4EALDH1A1HPGDGAAGALR3 | |
| SCHEMBL9475931 | 0.82 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL7381624 | 0.82 | KDM4E (0.57) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL11023795 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL4098490 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL10853277 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1HPGDGAA | |
| SCHEMBL11017408 | 0.81 | KDM4E (0.46) | KDM4EHSD17B10ALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0190265-B1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-08 | — | — | EP | claimed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080176827-A1 | New Pyridine Analogues VII 543 | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008085118-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| EP-0190265-B1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0190265-A4 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1987-07-09 | — | — | EP | disclosed |
| US-4657919-A | CARDIOVASCULAR DISORDERS | E. I. DU PONT DE NEMOURS & CO. (US) | 1987-04-14 | — | — | US | disclosed |
| EP-0190265-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1986-08-13 | — | — | EP | disclosed |
| WO-1986001202-A1 | PYRIDONE ESTERS AS INOTROPIC AGENTS | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-02-27 | — | — | WO | disclosed |
| US-4555517-A | Pyridone esters as inotropic agents | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176827-A1 | New Pyridine Analogues VII 543 | P2RY12, P2RY11, P2RY4 | KDM4E 2906/4885HSD17B10 3380/4885ALDH1A1 1634/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | KDM4E 1759/4885HSD17B10 3283/4885ALDH1A1 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.